Your browser does not support JavaScript! before use docindia please enable Javascript on your browser

Drug Facts


DESCRIPTION SECTION

Each capsule contains:

Naxproxen, ESP ..........500 mg


DESCRIPTION SECTION

Dosage and Use: For dosage recommendations

and other important prescribing information, read accompanying insert.


STORAGE AND HANDLING SECTION

Store at 20 to 25 C (68 to 77 F); excursions

permitted to 15 to 30 C (59 to 86 F)[See

USP Controlled Room Temperature]

Dispense in well-closed, light-resistant containers

as defined in the USP.  


BOXED WARNING SECTION

BOXED WARNING

Cardiovascular Risk

-NSAIDs may cause an increased risk of serious cardiovascular thrombotic events,

myocardial infarction, and stroke, which can be fatal.

-Naproxen as Naproxen Tablets, USP is contraindicated for the treatment of peri-operative

pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

Gastrointestinal Risk

-NSAIDs may cause an increased risk of serious gastrointestinal adverse events including

bleeding, ulceration. and perforation of the stomach or intestines, which can be fatal.


DESCRIPTION SECTION

DESCRIPTION

Naproxen, USP is a proprionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs.


CLINICAL PHARMACOLOGY SECTION

CLINICAL PHARMACOLOGY

Pharmacodynamics - Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and

antipyretic properties.


CLINICAL STUDIES SECTION

CLINICAL STUDIES

General Information - Naproxen has been studied in patients with rheumatoid arthritis, osteoarthritis,

juvenile arthritis, ankylosing spondylitis, tendonitis and bursitis, and acute gout.


INDICATIONS & USAGE SECTION

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of naproxen tablets, USP and other treatments

before deciding to sue naproxen tablets, USP.


CONTRAINDICATIONS SECTION

CONTRAINDICATIONS

Naproxen tablets, USP are contraindicated in patients with known hypersensitivity to naproxen, USP.


WARNINGS SECTION

WARNINGS

Cardiovascular Effects - Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective

and non-selective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV)

thrombotic events, myocardial infarction, and stroke, which can be fatal.


PRECAUTIONS SECTION

PRECAUTIONS

General - Naproxen - containing products such as naproxen tablets, and other naproxen products should

not be used concomitantly since they all circulate in the plasma as the naproxin anion.


ADVERSE REACTIONS SECTION

ADVERSE REACTIONS

Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis

or osteoarthritis are listed below.


OVERDOSAGE SECTION

OVERDOSAGE

Symptoms and Signs   Significant naproxen overdosage may be characterized by lethargy, dizziness,

drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, transient alterations in liver function,

hypoprothrombinemia, renal dysfunction, metabolic acidosis, apnea, disorientation or vomiting.


DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION

Carefully consider the potential benefits and risks of naproxen tablets, USP and other treatment

options before deciding to use naproxen tablets, USP.


PATIENT MEDICATION INFORMATION SECTION

MEDICATION GUIDE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

(See the end  of this Medication Guide for a list of prescription NSAID medicines.)


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL